802 Results
Sort By:
Published on May 21, 2015
Based on the most current data, approximately 14% of men will be diagnosed with prostate cancer at some point during their lifetime. If detected early, long term clinical prognosis is very good, however in many cases, prostate cancer can become metastatic and drug resistant tumor rates are on the rise. …
Published on April 20, 2015
The Massachusetts based Foundation Medicine, which develops, manufactures, and sells genomic analysis diagnostics for solid and circulating cancers has announced a collaboration with the National Cancer Institute (NCI) on the Exceptional Responders Initiative (ERI). The alliance is for an exploratory study to investigate the unique molecular indicators of tumors associated…
Published on March 1, 2015
As next-generation sequencing (NGS) makes genetic testing for a wide range of human diseases increasingly commonplace, facile methods for validating the efficacy of those tests are essential. Federal regulatory standards embodied in the Clinical Laboratory Improvement Amendments (CLIA), for instance, are designed to ensure that these tests reliably achieve certain…
Published on February 10, 2015
Roche has acquired Signature Diagnostics for an undisclosed price. The deal is designed to strengthen Roche’s cancer diagnostics effort with Signature’s expertise in both biobanks and next-generation sequencing (NGS) assays, and is the pharma giant’s fifth deal in less than a year focused on molecular diagnostics and data analysis. Signature…
Published on November 19, 2014
Genomic technologies enabling relatively simple, rapid, and costeffective high-throughput testing of RNA-based multiplexed signatures in blood samples would greatly facilitate wide-scale adoption of molecular diagnostic tests in clinical medicine. Tests like CardioDx’ Corus CAD and CAREDx’ Allomap represent the first generation of products designed to improve diagnosis, predict therapeutic response, monitor drug responses in patients, and determine disease prognosis from a simple blood…
Published on October 10, 2014
Precision cancer therapy firm Perthera is partnering with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) to conduct a translational research program aimed at assessing the utility of integrating next-generation sequencing, proteomic, and phospho-proteomic data in oncology developmental therapeutics and…
Published on October 8, 2014
As the genomic age takes hold, the medical and pharmaceutical industries are just now beginning to scratch the surface of innovation in testing for a wide range of diseases, as well as creating highly targeted therapies based on an individual’s genetic makeup. But as clinicians embrace the great promise of…
Published on October 7, 2014
A project team led by Benjamin Darbro, M.D., Ph.D., director of the Shivanand R. Patil Cytogenetics and Molecular Laboratory at the University of Iowa Hospital and Clinics, has won the inaugural Appistry Pipeline Challenge for developing and executing a pipeline designed to reduce the costs and turnaround times associated with…
Published on September 10, 2014
There are huge benefits to genomic tumor assessment, both for better treatment now, and later, if first-line treatments fail. But I don’t think many cancer patients—and even some physicians—fully understand how important tumor sequencing can be to successful cancer treatment. Yet. This is not surprising. Outside of a few tests…
Published on September 5, 2014
Molecular cytology diagnostics firm Veracyte is acquiring Massachusetts-based company Allegro Diagnostics for $21 million—$7.8 million in cash, $13.2 million in Veracyte common stock. Allegro's primary focus is on developing diagnostic tests for lung cancer, and Veracyte plans to launch Allegro's lead lung cancer test in the second half of 2015.…
Published on July 17, 2014
A San Diego startup whose technology promises to enable the clinical use of genomics by radically reducing the cost and time of analyzing next-generation sequencing (NGS) data is attractive enough to have drawn Gregory Lucier among investors that have joined to raise $10 million in Series A financing. Lucier has…
Published on June 23, 2014
Cancer Genetics (CGI) said today it plans to acquire Gentris, in an up-to-$6.25 million deal that the buyer said will significantly expand its client base beyond oncology diagnostics, through added capabilities in genomic profiling for clinical trials as well as in pharmacogenomics. “We view this acquisition as part of our…
Published on June 16, 2014
Horizon Discovery and LGC have been offered a research grant of £360,224 ($608,000) by the Technology Strategy Board, the U.K.’s innovation agency. The grant is awarded under the board’s collaborative research and development project “Improving Cell and Tissue Analysis for Stratified Medicine” and will fund a joint project run by…
Published on June 12, 2014
Angelina Jolie’s self-disclosure of the BRCA1 gene mutation that led her to undergo a double mastectomy helped normalize the concept of genetic testing and counseling more than a year ago. Clinical practitioners agree that more patients are aware of genetic testing and counseling because of what has been called the…
Published on June 11, 2014
The American Society of Human Genetics (ASHG) and The Jackson Laboratory (JAX) said today they have launched a new collaboration to produce and deliver educational programs designed to integrate genetic and genomic advances into clinical healthcare practice. The programs will educate groups such as students and trainees, primary care and…